Search: 
Content on WikiHealthCare is created by the community of registered users. Joint Commission sponsorship of the site is not an endorsement of the content or guarantee of its accuracy (Disclaimer).

ACEi Or ARb Prescribed At Discharge For LVSD

ACEI therapy reduces mortality and morbidity in patients with left ventricular systolic dysfunction (LVSD) after AMI (Flather, 2000; Pfeffer, 1992; Torp-Peterson, 1999; and Yusuf, 2000). Recent clinical trials have also established ARB therapy as an acceptable alternative to ACEI, especially in patients with heart failure and/or LVSD who are ACEI intolerant (Granger, 2003 and Pfeffer, 2003). National guidelines strongly recommend ACEI for patients hospitalized with AMI who have either clinical heart failure or LVSD (Antman, 2004 and Braunwald, 2002). Guideline committees have also supported the inclusion of ARBs in performance measures for AMI (Antman, 2004). Despite these recommendations, ACEIs remain under-utilized in eligible older patients hospitalized with AMI (Jencks, 2000).
edittopic Edit


handPlease Login to post reports.

Research & Resource Reports

Sort by:   Display: of 0 HELPMore search options


handPlease Login to post reports.

Field Experiences

Sort by:   Display: of 2 HELPMore search options

ACEI/ARB Compliance

Rural; Teaching; 301-400 beds; Clarksburg, WV
Posted by MarkPovroznik on 08/12/2008

  
Maintaining nearly 100% compliance. Utilizing various redundant processes to trigger information needed and to capture acceptable contraindications.
  

CHF compliance

Urban; Non-teaching; 50-100 beds; Arroyo Grande, Ca
Posted by VillaInfanto on 08/19/2008

  
Made improvements (10th lower percentile to top 25%) by having Case Mgt insert physician CHF progress forms in chart. The forms have all the core measure triggers. Utilize computerized discharge instructions that automatically include ACEI and ARB and medication info.
  


Links


References

  • Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP, Pearle DL, Sloan MA, Smith SC Jr; American College of Cardiology; American Heart Association; Canadian Cardiovascular Society. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). J Am Coll Cardiol. 2004 Aug 4;44(3):671-719.
  • Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, Jones RH, Kereiakes D, Kupersmith J, Levin TN, Pepline CJ, Schaeffer JW, Smith EE III, Steward DE, Theroux P. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). 2002.
  • Flather MD, Yusuf S, Kober L et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000; 355(9215):1575-1581.
  • Granger CB, McMurray? JJ, Yusuf S et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003;362:772-776.
  • Jencks SJ, Cuerdon T, Burwen DR, Fleming B, Houck PM, Kussmaul AE, Nilasena DS, Ordin DL, Arday DR. Quality of medical care delivered to Medicare beneficiaries: a profile at state and national levels. JAMA. 2000;284:1670-1676.
  • Krumholz HM, Anderson JL, Brooks NH, Fesmir FM, Lambrew CT, Landrum MB, Weaver, WD,Whyte J. ACC/AHA Clinical Performance Measures for Adults With ST-Elevation and Non–ST-Elevation Myocardial Infarction: a report of the ACC/AHA Task Force on Performance Measures (ST-Elevation and Non–ST-Elevation Myocardial Infarction Performance Measures Writing Committee). J Am Coll Cardiol 2006;47:236–65. Available at http://www.acc.org and http://www.americanheart.org.
  • Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ, Jr., Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, for the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. N Engl J Med. 1992;327:669-77.
  • Pfeffer MA, McMurray? JJ, Velazquez EJ et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893-1906.
  • Torp-Pedersen C, Kober L. Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evaluation. Lancet 1999; 354(9172):9-12.
  • Yusuf S, Pepine CJ, Garces C et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992; 340(8829):1173-1178.
edittopic Edit

Recent Comments on ACEi Or ARb Prescribed At Discharge For LVSD

hand Start a discussion on this topic!

r7 - 16 Nov 2007 - 11:59:33 - BretteTschurtz
WikiRing: Professional Wiki Innovation and SupportWikiRing.com
This site is powered by the TWiki collaboration platform
Copyright © by the contributing authors. All material on this collaboration platform is the property of the contributing authors.
WikiHealthCare is a registered trademark of The Joint Commission, a US-registered 501(c)(3) tax-deductible nonprofit organization.
Policies | Guidelines | User Agreement | Privacy Policies | Disclaimer | GNU License
Syndicate this site RSSATOM